Purchase Order 75N98026P01624
Award Date 9/14/26
Potential Completion Date 9/13/27
Potential Value $50K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20850, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...
- This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services. The $10,656.00 contract is for a pharmacokinetic (PK) study in mice, with a final completion date of September 21, 2026. The work will be performed at Pharmaron's division in Louisville, Kentucky....
- This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
- This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
- This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation. The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. This...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
- This is a $4,130 firm-fixed-price purchase order contract awarded by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency, to Pharmaron (Exton) Lab Services LLC, doing business as Absorption Systems. The contract is for an in-vivo pharmacokinetic (PK) study to determine the optimal formulation for dosing cytochrome P inhibitors and analyzing their concentrations in mouse plasma. This contract is not designated as a small business set-aside. Pharmaron is a global...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...
- The National Institute on Drug Abuse awarded a purchase order to Pharmaron, Inc. for $117,435 on August 9, 2022, to evaluate NNMT inhibitors in metabolic disorders. The order is firm fixed price with no small business set-aside. Place of performance is Louisville, Kentucky. The ultimate completion date was August 8, 2023. The award was issued as part of an HHS UDO SPRINT exercise to de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) ahead of...
- This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...